Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion
- PMID: 3934784
- DOI: 10.1016/0049-3848(85)90326-3
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion
Abstract
A cause-effect relation between the synthesis and release of prostaglandins and fibrinolytic activation has been suggested. We have reinvestigated this relation in a double-blind, placebo-controlled, cross-over study with cyclooxygenase inhibitors (aspirin and indomethacin) and a thromboxane synthase inhibitor (dazoxiben) in nine healthy volunteers. Euglobulin fibrinolytic activity (EFA) and tissue-type plasminogen activator antigen level (t-PA:Ag) were studied before and after 10 min of venous occlusion. Despite effective suppression of prostaglandin synthesis by aspirin and indomethacin and enhanced prostacyclin formation by dazoxiben, baseline EFA and t-PA:Ag levels did not significantly change within 2 hours after ingestion of the different drugs. The release of t-PA by venous occlusion was not altered by any of the drugs. Thus, our study does not support the hypothesis that prostaglandins play a significant role in the modulation of the synthesis or release of t-PA.
Similar articles
-
Prostacyclin is required for t-PA release after venous occlusion.Am J Physiol. 1994 Feb;266(2 Pt 2):H429-34. doi: 10.1152/ajpheart.1994.266.2.H429. Am J Physiol. 1994. PMID: 7511345
-
Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids.Arterioscler Thromb. 1992 Oct;12(10):1191-7. doi: 10.1161/01.atv.12.10.1191. Arterioscler Thromb. 1992. PMID: 1390591 Clinical Trial.
-
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.J Clin Invest. 1987 Nov;80(5):1435-45. doi: 10.1172/JCI113223. J Clin Invest. 1987. PMID: 2960694 Free PMC article. Clinical Trial.
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
-
Prostaglandins and leprosy. A role for aspirin?Lepr Rev. 1989 Mar;60(1):51-8. doi: 10.5935/0305-7518.19890008. Lepr Rev. 1989. PMID: 2657300 Review.
Cited by
-
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.Blood. 2007 Mar 15;109(6):2285-92. doi: 10.1182/blood-2006-01-010645. Epub 2006 Dec 5. Blood. 2007. PMID: 17148593 Free PMC article. Review.
-
Aspirin in cardiovascular disease.Drugs. 1988 Feb;35(2):154-76. doi: 10.2165/00003495-198835020-00005. Drugs. 1988. PMID: 3281822 Review.